Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Welglim PM 2
Welglim PM 2 is an advanced oral antidiabetic combination therapy formulated with Glimepiride, Pioglitazone, and Metformin HCL. This triple-drug therapy effectively addresses insulin resistance, pancreatic beta-cell dysfunction, and excessive hepatic glucose output—key factors in type 2 diabetes mellitus (T2DM). It helps achieve stable glycemic control while reducing the risk of diabetes-related complications.
Uses of Welglim PM 2
Welglim PM 2 is indicated for the treatment of:
Type 2 diabetes mellitus (T2DM) in patients requiring multi-targeted therapy
Poorly controlled diabetes despite monotherapy or dual therapy
Insulin resistance and beta-cell dysfunction
Benefits of Welglim PM 2
Triple-Action Formula: Stimulates insulin secretion, enhances insulin sensitivity, and reduces hepatic glucose production
Improved Glycemic Control: Lowers fasting and postprandial blood sugar levels
Reduces Insulin Resistance: Helps the body utilize insulin more effectively
Minimizes Risk of Diabetes Complications: Protects against cardiovascular and metabolic disorders
Mechanism of Action of Welglim PM 2
Glimepiride (Sulfonylurea): Stimulates pancreatic beta cells to release insulin
Pioglitazone (Thiazolidinedione): Enhances insulin sensitivity at peripheral tissues
Metformin HCL (Biguanide): Suppresses hepatic glucose production and improves glucose uptake in muscles